Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-RD06 in Relapsed or Refractory CD19+ B-cell Hematological Malignancy
NCT04226989Phase 1Unknown
- Start
- Feb 2020
- Primary completion
- Feb 2022
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT-RD06 in B cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma. Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-emergent adverse events at 2 years. Status: unknown.
02
Drugs
CT-RD06
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04226989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04226989.